Drug Trial Radar · NCT05765851
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
128
Planned (sponsor's estimate)
Start
May 30, 2023
Primary completion
May 31, 2029
Study completion Feb 28, 2031
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- Mar 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
DS-1103aDrug
One IV infusion Q3W on Day 1 of each 21-day cycle
T-DXdDrug
One IV infusion Q3W on Day 1 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose-limiting Toxicities (Dose Escalation)Time frame: From Cycle 1 Day 1 to Cycle 2 Day 21 (each cycle is 21 days)
- Objective Response Rate Assessed by Blinded Independent Central Review Following DS-1103a Combination Therapy (Dose Expansion)Time frame: Baseline (Dose Expansion) up until documented progressive disease, unacceptable toxicity, death, lost to follow-up, or withdrawal by the participant, up to approximately 5 years 11 months
- Number of Participants with Dose-limiting Toxicities Following DS-1103a Combination Therapy (Dose Expansion; Cohort 2 Safety Run In and Japanese Population Tolerability Assessments)Time frame: From Cycle 1 Day 1 to Cycle 1 Day 21 (each cycle is 21 days)
- Overall Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events (Dose Escalation and Expansion; Cohort 2 Safety Run In and Japanese Population Tolerability Assessments)Time frame: Screening through long-term follow up, up to approximately 91 months
Locations
15 sites in 6 countries. Site status is shown where the registry gives one.
Florida Cancer Specialists
Sarasota, Florida · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Lifespan Cancer Institute
Providence, Rhode Island · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
NEXT Oncology
Fairfax, Virginia · Recruiting
Princess Margaret Cancer Centre, University Health Network
Toronto, Canada · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Oncopole - Institut Claudius Regaud
Toulouse, France · Recruiting
Gifu University Hospital
Gifu, Japan · Recruiting
Shizuoka Cancer Center
Nakatogari, Japan · Recruiting
The University of Osaka Hospital
Osaka, Japan · Recruiting
The Cancer Institute Hospital Of JFCR
Tokyo, Japan · Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Spain · Recruiting
National Cheng Kung University Hospital
Tainan, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.